Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

2.

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U.

Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23. No abstract available.

PMID:
27659716
3.

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M.

Ann Hematol. 2016 Oct;95(11):1805-10. doi: 10.1007/s00277-016-2775-y. Epub 2016 Aug 10.

PMID:
27510179
4.

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.

Oelschlaegel U, Alexander Röhnert M, Mohr B, Sockel K, Herold S, Ehninger G, Bornhäuser M, Thiede C, Platzbecker U.

Leukemia. 2016 Feb;30(2):517-20. doi: 10.1038/leu.2015.158. Epub 2015 Jun 24. No abstract available.

5.

Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Oelschlaegel U, Westers TM, Mohr B, Kramer M, Parmentier S, Sockel K, Thiede C, Bornhäuser M, Ehninger G, van de Loosdrecht AA, Platzbecker U.

Haematologica. 2015 Mar;100(3):e93-6. doi: 10.3324/haematol.2014.115725. Epub 2014 Nov 25. No abstract available.

6.

Comment to the response to "severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome".

Oelschlaegel U, Parmentier S, Platzbecker U.

Ann Hematol. 2013 Apr;92(4):575-6. doi: 10.1007/s00277-012-1570-7. Epub 2012 Sep 9. No abstract available.

PMID:
22960851
7.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
8.

Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome.

Parmentier S, Meinel J, Oelschlaegel U, Mohr B, Ehninger G, Schaich M, Platzbecker U.

Ann Hematol. 2012 Dec;91(12):1979-81. doi: 10.1007/s00277-012-1488-0. Epub 2012 May 11. No abstract available.

PMID:
22576312
9.

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C.

Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2.

10.

Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

Schaich M, Röllig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H, Schäfer-Eckart K, Aulitzky W, Kaufmann M, Bodenstein H, Tischler J, Ho A, Krämer A, Bornhäuser M, Schetelig J, Ehninger G.

J Clin Oncol. 2011 Jul 1;29(19):2696-702. doi: 10.1200/JCO.2010.33.7303. Epub 2011 May 23.

PMID:
21606413
11.

Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.

Bornhäuser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Hölig K, Radke J, Tuve S, Wermke M, Wehner R, Jähnisch H, Bachmann MP, Rieber EP, Schetelig J, Ehninger G, Schmitz M.

Blood. 2011 Jun 30;117(26):7174-84. doi: 10.1182/blood-2010-09-308569. Epub 2011 May 3.

PMID:
21540460
12.

Reply to: 'Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity' by Kern et al.

Oelschlaegel U, Mohr B, Schaich M, Kroschinsky F, Parmentier S, Bornhäuser M, Ehninger G, Thiede C.

Leukemia. 2011 May;25(5):895-7. doi: 10.1038/leu.2011.23. Epub 2011 Feb 18. No abstract available.

PMID:
21331074
13.

Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia.

Oelschlaegel U, Koch S, Mohr B, Schaich M, Falini B, Ehninger G, Thiede C.

Leukemia. 2010 Oct;24(10):1813-6. doi: 10.1038/leu.2010.178. Epub 2010 Aug 19. No abstract available.

PMID:
20724983
14.

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.

Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, Platzbecker U, Stuhlmann R, Schuler U, Soucek S, Kramer M, Mohr B, Oelschlaegel U, Stölzel F, von Bonin M, Wermke M, Wandt H, Ehninger G, Schaich M; Study Alliance Leukemia.

Blood. 2010 Aug 12;116(6):971-8. doi: 10.1182/blood-2010-01-267302. Epub 2010 May 4.

PMID:
20442365
15.

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.

Jing D, Oelschlaegel U, Ordemann R, Hölig K, Ehninger G, Reichmann H, Ziemssen T, Bornhäuser M.

Bone Marrow Transplant. 2010 Oct;45(10):1489-96. doi: 10.1038/bmt.2009.381. Epub 2010 Jan 25.

PMID:
20098455
16.

Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.

Bornhäuser M, Oelschlaegel U, Platzbecker U, Bug G, Lutterbeck K, Kiehl MG, Schetelig J, Kiani A, Illmer T, Schaich M, Theuser C, Mohr B, Brendel C, Fauser AA, Klein S, Martin H, Ehninger G, Thiede C.

Haematologica. 2009 Nov;94(11):1613-7. doi: 10.3324/haematol.2009.007765.

17.

HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.

Oelschlaegel U, Mohr B, Schaich M, Schäkel U, Kroschinsky F, Illmer T, Ehninger G, Thiede C.

Cytometry B Clin Cytom. 2009 Sep;76(5):321-7. doi: 10.1002/cyto.b.20475.

18.

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.

Mohr B, Oelschlaegel U, Thiede C, Stewart MM, Ehninger G, Platzbecker U.

Haematologica. 2009 Mar;94(3):430-1. doi: 10.3324/haematol.13865. Epub 2009 Jan 30. No abstract available.

19.

Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.

Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G.

Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894.

20.

Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.

Fierro FA, Brenner S, Oelschlaegel U, Jacobi A, Knoth H, Ehninger G, Illmer T, Bornhäuser M.

Leukemia. 2009 Feb;23(2):393-6. doi: 10.1038/leu.2008.182. Epub 2008 Jul 10. No abstract available.

PMID:
18615106
21.

Cup-like acute myeloid leukemia: new disease or artificial phenomenon?

Kroschinsky FP, Schäkel U, Fischer R, Mohr B, Oelschlaegel U, Repp R, Schaich M, Soucek S, Baretton G, Ehninger G, Thiede C; DSIL (Deutsche Studieninitiative Leukämie) Study Group.

Haematologica. 2008 Feb;93(2):283-6. doi: 10.3324/haematol.11669. Epub 2008 Jan 26.

22.

Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.

Bornhäuser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, Thiede C.

Leukemia. 2007 Aug;21(8):1824-6. Epub 2007 May 3. No abstract available.

PMID:
17476275
23.

Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma.

Oelschlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K, Calandra G, Ehninger G, Platzbecker U.

Ann Hematol. 2007 Aug;86(8):569-73. Epub 2007 Apr 17.

PMID:
17437111
24.

Kidney transplantation substantially improves endothelial progenitor cell dysfunction in patients with end-stage renal disease.

Herbrig K, Gebler K, Oelschlaegel U, Pistrosch F, Foerster S, Wagner A, Gross P, Passauer J.

Am J Transplant. 2006 Dec;6(12):2922-8.

25.

Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.

Kroschinsky F, Hölig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, Oelschlaegel U, Schaich M, Hänel M, Bornhäuser M, Ehninger G.

Transfusion. 2006 Aug;46(8):1417-23.

PMID:
16934080
26.

Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation.

Auffermann-Gretzinger S, Eger L, Bornhäuser M, Schäkel K, Oelschlaegel U, Schaich M, Illmer T, Thiede C, Ehninger G.

Transplantation. 2006 Mar 27;81(6):866-73.

PMID:
16570010
27.

Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.

Kroschinsky F, Hölig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M, Oelschlaegel U, Bornhauser M, Rall G, Rutt C, Ehninger G.

Haematologica. 2005 Dec;90(12):1665-71.

28.

Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells.

Herbrig K, Haensel S, Oelschlaegel U, Pistrosch F, Foerster S, Passauer J.

Ann Rheum Dis. 2006 Feb;65(2):157-63. Epub 2005 Jun 23.

29.

PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.

Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P.

Atherosclerosis. 2005 Nov;183(1):163-7.

PMID:
15907852
30.

Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells.

Bornhäuser M, Eger L, Oelschlaegel U, Auffermann-Gretzinger S, Kiani A, Schetelig J, Illmer T, Schaich M, Corbeil D, Thiede C, Ehninger G.

Leukemia. 2005 Jan;19(1):161-5. No abstract available.

PMID:
15510205
31.

Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis.

Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J.

Am J Kidney Dis. 2004 Nov;44(5):840-9.

PMID:
15492950
32.

HPC enumeration with the Sysmex XE-2100 can guide further flow cytometric CD34(+) measurements and timing of leukaphereses.

Oelschlaegel U, Bornhaeuser M, Thiede C, Ehninger G, Hoelig K.

Cytotherapy. 2003;5(5):414-9.

PMID:
14578103
33.

A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes.

Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Naumann R, Bux Y, Ehninger G.

Clin Lab Haematol. 2001 Apr;23(2):81-90.

PMID:
11488846
34.

Flow cytometric DNA-quantification of three-color immunophenotyped cells for subpopulation specific determination of aneuploidy and proliferation.

Oelschlaegel U, Freund D, Range U, Ehninger G, Nowak R.

J Immunol Methods. 2001 Jul 1;253(1-2):145-52.

PMID:
11384676
35.

Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow.

Nowak R, Oelschlaegel U, Schuler U, Zengler H, Hofmann R, Ehninger G, Andreeff M.

Cytometry. 1997 Feb 15;30(1):47-53.

PMID:
9056742

Supplemental Content

Loading ...
Support Center